See more : DXI Capital Corp. (DXIEF) Income Statement Analysis – Financial Results
Complete financial analysis of Concord Medical Services Holdings Limited (CCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concord Medical Services Holdings Limited, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Austpac Resources N.L. (APG.AX) Income Statement Analysis – Financial Results
- Decorous Investment and Trading Company Limited (DITCO.BO) Income Statement Analysis – Financial Results
- The Rank Group Plc (RNK.L) Income Statement Analysis – Financial Results
- Nevada Lithium Resources Inc. (NVLH.CN) Income Statement Analysis – Financial Results
- Godo Steel, Ltd. (5410.T) Income Statement Analysis – Financial Results
Concord Medical Services Holdings Limited (CCM)
About Concord Medical Services Holdings Limited
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 537.40M | 472.09M | 485.63M | 223.01M | 198.36M | 190.90M | 330.98M | 455.04M | 616.49M | 606.88M | 563.12M | 455.65M | 450.13M | 389.52M | 292.44M | 171.79M |
| Cost of Revenue | 614.01M | 624.49M | 542.53M | 209.93M | 214.19M | 171.14M | 232.98M | 286.54M | 353.34M | 274.56M | 217.66M | 164.52M | 159.42M | 122.70M | 87.56M | 45.60M |
| Gross Profit | -76.61M | -152.41M | -56.90M | 13.08M | -15.83M | 19.76M | 98.00M | 168.50M | 263.15M | 332.32M | 345.47M | 291.13M | 290.71M | 266.82M | 204.88M | 126.19M |
| Gross Profit Ratio | -14.26% | -32.28% | -11.72% | 5.87% | -7.98% | 10.35% | 29.61% | 37.03% | 42.69% | 54.76% | 39.77% | 49.68% | 64.58% | 68.50% | 70.06% | 73.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 308.71M | 311.16M | 347.75M | 294.82M | 315.13M | 291.85M | 237.65M | 205.91M | 132.95M | 53.58M | 84.51M | 61.11M | 114.40M | 70.01M | 29.82M | 18.87M |
| Selling & Marketing | 56.30M | 61.48M | 53.68M | 25.76M | 30.24M | 21.72M | 43.61M | 70.09M | 112.82M | 95.10M | 104.67M | 53.91M | 37.45M | 17.15M | 7.68M | 5.50M |
| SG&A | 386.38M | 372.64M | 401.42M | 320.58M | 345.38M | 313.57M | 281.25M | 276.00M | 245.77M | 148.67M | 189.17M | 115.02M | 151.85M | 87.16M | 37.50M | 24.37M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 8.50M | 76.09M | 5.43M | 28.60M | 61.12M | 23.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 386.38M | 372.64M | 401.42M | 329.08M | 421.46M | 319.01M | 309.85M | 337.13M | 268.89M | 148.67M | 189.17M | 103.39M | 151.85M | 87.16M | 37.50M | 24.37M |
| Cost & Expenses | 1.00B | 997.13M | 943.95M | 539.01M | 635.66M | 490.14M | 542.83M | 623.67M | 622.23M | 423.23M | 406.83M | 267.92M | 311.27M | 209.86M | 125.06M | 69.96M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.60M | 13.36M | 7.87M | 948.00K | 430.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.45M | 7.45M | 6.89M | 7.46M |
| Depreciation & Amortization | 118.83M | 123.19M | 94.46M | 70.79M | 56.35M | 45.02M | 89.45M | 127.81M | 157.25M | 198.07M | 179.64M | 148.58M | 120.64M | 109.69M | 78.17M | 38.13M |
| EBITDA | -344.16M | -401.86M | -363.86M | -236.72M | -304.85M | -248.79M | -93.80M | 20.31M | 174.63M | 381.72M | 335.94M | 332.63M | -161.31M | 291.93M | 246.29M | 140.38M |
| EBITDA Ratio | -48.65% | -123.11% | -68.24% | -92.56% | -132.90% | -110.82% | -21.79% | 15.01% | 11.01% | 36.40% | 21.26% | 32.51% | 33.82% | 46.79% | 57.56% | 81.72% |
| Operating Income | -462.99M | -525.05M | -458.32M | -316.00M | -437.29M | -299.24M | -211.86M | -168.63M | -5.74M | 183.65M | 156.30M | 184.05M | 138.86M | 179.67M | 167.38M | 101.83M |
| Operating Income Ratio | -86.15% | -111.22% | -94.38% | -137.89% | -220.45% | -156.76% | -64.01% | -37.06% | -0.93% | 30.26% | 17.92% | 30.71% | 30.85% | 46.12% | 57.24% | 59.27% |
| Total Other Income/Expenses | -92.61M | -314.85M | -70.92M | -125.65M | 46.22M | 74.00M | -42.04M | -35.97M | 489.00K | -8.00M | -12.03M | -2.91M | -3.73M | -4.88M | -6.16M | 578.00K |
| Income Before Tax | -555.59M | -839.90M | -529.24M | -441.65M | -391.08M | -225.25M | -253.90M | -204.60M | -5.25M | 175.65M | 144.27M | 181.14M | -165.03M | 174.79M | 161.22M | 102.40M |
| Income Before Tax Ratio | -103.39% | -177.91% | -108.98% | -198.04% | -197.15% | -117.99% | -76.71% | -44.96% | -0.85% | 28.94% | 17.36% | 29.41% | -36.66% | 44.87% | 55.13% | 59.61% |
| Income Tax Expense | 24.57M | 70.91M | 6.57M | 37.62M | 38.99M | 34.05M | 31.79M | 60.49M | 74.03M | 80.85M | 63.84M | 54.25M | 46.32M | 43.87M | 36.40M | 23.34M |
| Net Income | -297.66M | -489.66M | -271.43M | -309.99M | -307.05M | -234.88M | -284.32M | -261.87M | -78.30M | 124.71M | 85.89M | 123.24M | -215.00M | 129.40M | 124.83M | 79.07M |
| Net Income Ratio | -55.39% | -103.72% | -168.98% | -300.39% | -278.54% | -188.18% | -85.90% | -57.55% | -12.70% | 16.35% | 13.34% | 27.05% | -47.77% | 33.22% | 42.69% | 46.03% |
| EPS | -68.14 | -112.09 | -187.85 | -153.35 | -127.27 | -82.83 | -65.57 | -60.14 | -17.46 | 22.08 | 16.69 | 2.67 | -4.53 | 2.67 | 1.86 | -25.89 |
| EPS Diluted | -68.14 | -112.09 | -187.85 | -153.35 | -127.27 | -82.83 | -65.57 | -60.14 | -17.46 | 21.95 | 16.69 | 2.67 | -4.53 | 2.67 | 1.86 | -25.89 |
| Weighted Avg Shares Out | 4.37M | 4.37M | 1.44M | 2.02M | 2.41M | 2.84M | 4.34M | 4.35M | 4.48M | 5.68M | 5.15M | 46.07M | 47.42M | 48.68M | 24.88M | 19.16M |
| Weighted Avg Shares Out (Dil) | 4.37M | 4.37M | 4.37M | 4.37M | 4.34M | 4.34M | 4.34M | 4.35M | 4.48M | 4.51M | 4.50M | 46.07M | 47.42M | 48.68M | 24.88M | 19.16M |
Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
Concord Medical Announces Listing of Its Subsidiary on The Stock Exchange of Hong Kong Limited
Canagold Appoints Chris Pharness as Senior Vice President Sustainability and Permitting
Concord Medical Schedules 2023 Annual Meeting of Shareholders
Concord Medical Reports Financial Results for the First Half of 2023
Cincom® Integrates with Duck Creek to Streamline Customer Communication Processes for Insurers
FUJIFILM Business Innovation Hong Kong and Quadient Celebrate 10-year Partnership
Presto Completes $1B SPAC Merger to Go Public
Concord Medical Is Shortlisted for the "5G+Healthcare" Pilot Project
Concord Medical Files 2020 Annual Report on Form 20-F
Source: https://incomestatements.info
Category: Stock Reports